PRDM9 and colonic neoplasm: Additionally, disrupting the scaffolding capabilities of other histone methyltransferase complexes, through the use of WD repeat-containing protein 5 (WDR5) inhibitors, demonstrated antitumor efficacy in preclinical models of colon cancer [105].